Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4606]

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy

ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy

$ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic leukaemia$

ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic...

NCRI 2012: From cancer genomes to personalised medicine

NCRI 2012: From cancer genomes to personalised medicine

NICE gives go ahead to ipilimumab for advanced melanoma

NICE gives go ahead to ipilimumab for advanced melanoma

ESMO 2012: Most cancer patients prepared to delay treatment to benefit from personalised care

ESMO 2012: Most cancer patients prepared to delay treatment to benefit from personalised care

Personalised medicine promises radical improvements to European healthcare

Personalised medicine promises radical improvements to European healthcare

Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer

Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer

Study highlights potential drug target for one in ten breast cancers

Study highlights potential drug target for one in ten breast cancers

Epigenetic drug discovery collaboration

Epigenetic drug discovery collaboration

More from ecancer